Market Reports

Digitalisation in specialty chemicals and pharmaceuticals

Paige Marie Morse, Industry Director, AspenTech talks to Dr Kevin Robinson about accelerating innovation and optimising the value chain with digital technologies

Supporting precision with precision

As biologics steadily grow in pipeline development and commercialisation, they inherently require precise and meticulous support to ensure effective delivery to the patient

The economic advantages of continuous flow chemistry

Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit

The modularisation of chemical API synthesis

The modularisation of chemical synthesis pathways in pharmaceutical production can improve overall plant efficiency and reduce planning time. Glatt Ingenieurtechnik has optimised the active pharmaceutical ingredient (API) synthesis process and developed bespoke plant designs for several international customers

Rare diseases: understanding the patient journey

In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research

A new paradigm in vaccines and cancer treatments

Specialist pharmaceutical company N4 Pharma is developing Nuvec, a unique non-viral adjuvant delivery system for vaccines and cancer treatments. This silica nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines. Dr Kevin Robinson recently caught up with Nigel Theobald, CEO of N4 Pharma, to find out more

Fuelling pharma’s innovation engines

Wishing to assess the current state of Alcami’s target market, Dr Kevin Robinson recently sat down with President and CEO, Dr Stephan Kutzer, to discuss its health, innovation and future aspirations

Broad stripes, bright stars and a thriving pharmaceutical industry: part I

According to one of Stephen Sondheim’s most well-known lyrics, “I like to be in America! OK by me in America!” But, given the geography, politics, population, regulation and funding that are unique to the United States, Dr Kevin Robinson looked west to the Land of the Free to find out how the pharmaceutical industry is faring amongst all the milk and honey

The hidden risk of contamination

Pharmaceutical companies may be unwittingly putting production processes at risk of contamination by fitting pumps with mechanical seals that fail to comply with industry regulations, says John Smiddy, European Sales and Technical Support Director for AESSEAL

A revolutionary method of liquid flow measurement

Pharmaceutical supplier opts for innovative hygienic flowmeter

Next-generation safety testing

In vitro genetic testing offers an ethical alternative to animal testing, which is also cheaper, faster and more reliable

Developments and the future of pharmaceutical packaging

With the global primary packaging market in the pharmaceutical sector expected to experience remarkable growth during the next few years, Dr Kevin Robinson asked a number of industry experts to comment on the hurdles, drivers and emerging trends that are influencing how drugs are formulated, packaged and delivered

Is the production of biologic drugs ready for an overhaul?

Is the industry ready for a new manufacturing model? Mark Emalfarb, President and CEO of Dyadic International, thinks so and explains why to Dr Kevin Robinson

Leaders of transformation

Haig Armaghanian, founder and CEO of Haig Barrett, explores how synthetic biology pioneers are revolutionising therapeutic development

Continuous manufacturing: the facts and the future

Many companies talk about continuous manufacturing (CM), but few speak with the experience of actually implementing a continuous process line. Dr Kevin Robinson spoke to GEA’s Richard Steiner to find out why

Looking back on 2018 and making predictions for 2019

As the global pharmaceutical industry transitions from the knowns of 2018 into the unknowns of 2019, Dr Kevin Robinson caught up with some of the key players in the market to assess the year that was and the 12 months to come in terms of upcoming trends and developments

Serialisation is not enough

A global technology leader in supply chain security, Systech’s revolutionary solution provides authentic, safe and connected products throughout the pharmaceutical supply chain. Dr Kevin Robinson recently caught up with CEO Ara Ohanian to find out more

Preparing PIs for post EU-FMD success

Ian Haynes of Excellis Europe explains how the company’s unique approach to enabling collaboration between parallel importers is helping to simplify the transition to serialisation post EU-FMD

Eliminating the time thieves

Comprehensive scientific process engineering (CSPE) cuts delivery times and accelerates the commissioning of pharmaceutical systems. Dr Kevin Robinson spoke to Optima Pharma’s Gerhard Breu to find out more

Formulating for success with ODTs

An ageing global population, consumer demand for greater convenience and the need to improve patient compliance are driving the development of new platforms for orally disintegrating dosage forms

Choosing effective granulation strategies for effervescent formulations

Effervescent tablets and instant drinks are attractive dosage forms for healthcare companies looking to meet the needs of modern patients and consumers

FMD: clarification for wholesalers, distributors and logistics partners

Christian Taylor, Serialisation Business Consultant at Zetes, clears up some of the key pain points when it comes to the practical application of the Falsified Medicines Directive (FMD)

Serialisation and data connectivity: Part II

The new wrinkle in your supply chain, <a href='https://www.manufacturingchemist.com/news/article_page/Serialisation_and_data_connectivity_Part_I/147850'>click here to read part I</a>

Serialisation and data connectivity: Part I

The new wrinkle in your supply chain

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    How CRDMOs are shaping the next generation of antibody-drug conjugates To explore how CRDMOs are leading innovation in ADC development, Dr Kevin Robinson spoke with Srivats Rajagopal, Senior Director, Cell and Protein Sciences, Biology Solutions at Aragen Life Sciences, about key technological advancements and evolving partnership models that are redefining what it means to outsource in this space
  2. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Start with the end in mind: the role of materials control in early CMC strategy for cell therapies Cell and gene therapy products are complex in their design, nature and mode of action. Because of this, the road to market can be a challenging one; littered with variables and failures, what might have been a valuable treatment often fails to reach much-in-need patients
  4. Freeze drying ADCs: points to consider for industrial applications As antibody-drug conjugates gain momentum in the pharmaceutical industry, manufacturers are increasingly looking to implement safe and effective process trains to produce them. Lyophilisation experts at GEA Pharma & Healthcare assess some of the most critical challenges and how to overcome them
  5. Rare diseases: understanding the patient journey In the shadow of Rare Disease Day on 28 February 2019, Dr Kevin Robinson met with Zizi Imatorbhebhe, Senior Director of Strategic Development and Head of PAREXEL’s Rare Disease Center of Excellence (RDCE), to discuss the future of rare disease research

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all